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Recently Lee et al. [1] published an interesting article 
that the long-term outcomes of autologous peripheral 
blood stem cell transplantation (PBSCT) to treat re-
fractory rheumatic diseases. They assessed 11 Korean pa-
tients who underwent PBSCT for refractory rheumatic 
diseases between 2002 and 2005 for outcomes including 
treatment response, adverse events, damage accrual, and 
survival. Overall 10-year survival rate was 70% with a 
40% recurrence rate and 20% treatment-related mortality 
rate. Their overall prognosis was not substantially differ-
ent from previous reports [2-4]. 
Hematopoietic stem cell transplantation (HSCT) has 
been proposed as an effective alternative treatment for re-
fractory rheumatic diseases. The first treatment with au-
tologous HSCT in a patient with rheumatic disease was 
described in 1996 [5]. Following the study, further autol-
ogous HSCT were performed, many under the framework 
of the European Society for Blood and Marrow Transplan-
tation (EBMT)/European League Against Rheumatism 
autoimmune disease stem cell project [6]. The EBMT reg-
istry now comprises over 1,800 HSCT procedures per-
formed to treat severe rheumatic diseases, including sys-
temic sclerosis (SSc), systemic lupus erythematosus 
(SLE), rheumatoid arthritis, juvenile idiopathic arthritis, 
and Sjögren's syndrome [7]. The aim of HSCT in auto-
immune disease is the eradication of autoreactive im-
mune cells and the regeneration of a naive, self-tolerant 
immune system [8]. To date, a variety of mechanisms 
have been proposed to explain the clinical effects (“im-
mune reboot”) of autologous HSCT in severe autoimmune 
diseases. Whereas a “debulking of inflammation” is an in-
stantaneous and predictable effect of any high-dose cyto-
toxic conditioning regimen, sustained clinical responses 
are best explained by long-term alterations in immune re-
constitution via thymic and/or extrathymic pathways. 
Shifts in T- and B-cell subpopulations from memory to 
naive cell dominance, with restoration of polyclonal T-cell 
receptor (TCR) diversity, correction of immune gene ex-
pression abnormalities, and other changes in T cells, B 
cells, plasmablasts, and natural killer cells support im-
mune re-education and tolerization with autologous 
HSCT [9]. HSCT renews the CD4+ T cell compartment 
and the Treg cell population, which is accompanied by an 
increase in the number of Treg cells and the re-establish-
ment of TCR diversity and function. The thymus is likely 
to have an important role in restoring this immune 
balance. Also, following transplantation, the B cell com-
partment becomes naive and the number of autoreactive 
antibodies decreases [7]. Clinical remission in auto-
immune disease after HSCT is the result of a true re-
configuration of the immune system instead of long-term 
immunosuppression. 
There is now sufficient evidence that HSCT can result in 
significant improvement of skin thickness and functional 
ability in SSc [10], while the recently completed 
Autologous Stem Cell Transplantation International 
Scleroderma trial demonstrated that HSCT can also pro-
long survival in selected patients with diffuse cutaneous 
SSc when compared with IV pulse cyclophosphamide 
[11]. In patients with SSc, autologous HSCT results in in-
creased treatment-related mortality within the first year 
but a considerable long-term, event-free survival benefit 
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afterwards.
One hundred fifteen autologous HSCTs for SLE have 
been reported to EBMT registry to date [12] since its first 
application in 1997 [13]. The two largest experiences so 
far come from the EBMT data registry (n=85; mean fol-
low-up: 25 months, range: 2∼123 months) [14] and from 
the single center pilot trial by Northwestern University 
(n=50; mean follow-up: 29 months, range: 6∼90 
months) [4]. The probability of five-year disease free sur-
vival was 50% in both studies, similar to results from 
smaller pilot studies [15]. Meanwhile, mechanistic stud-
ies have provided the proof of-concept that autologous 
HSCT not solely acts as prolonged immunosuppression, 
but rather rewires an autoreactive immune system into a 
self-tolerant state. This is achieved by two major princi-
ples; i) vast eradication of the autoreactive immunologic 
memory by an immunoablative regimen and ii) funda-
mental reconfiguration of the adaptive immune system 
[12]. This notion is reflected by a significant decrease or 
even disappearance of autoantibody levels (including an-
ti-dsDNA, anti-phospholipid and antinuclear antibodies), 
where chronic immunosuppression had been ineffective. 
Autologous HSCT is worth emphasizing in terms of its 
curative potential for treatment. The advantage of autolo-
gous HSCT is the almost complete ablation of the autor-
eactive memory for the resetting of the immune system 
becoming tolerant to self that can provide sustained re-
mission in the absence of chronic immunosuppression 
[12]. Compared to continued insufficient or failed chron-
ic immunosuppression, early use of autologous HSCT has 
the potential to protect against organ-failure and tox-
icity-related morbidity, improve quality of life and reduce 
socioeconomic costs.
However, autologous HSCT requires a careful selection 
of patients according to rheumatic diseases, consid-
eration of therapeutic alternatives, risks and benefits, and 
the expertise of the transplantation team. The results of 
autologous HSCT depend on better patient selection, 
center effect, transplantation early in the disease course 
and preemptive infection and other supportive therapies.
In addition to autologous HSCT, mesenchymal stem 
cells (MSCs), might also have potential for rheumatic dis-
ease treatment. MSCs have potent immunoregulatory 
and anti-inflammatory properties. The relative ease of 
harvesting MSCs and their stable phenotype in culture 
make the cells an attractive tool for cellular therapy in al-
loimmunity, autoimmunity, and inflammation [16]. This 
phenomenon has led to an increasing number of clinical 
trials. Recently clinical trials with this goal are ongoing in 
patients with rheumatic diseases. Further studies are nec-
essary to ascertain the concept of MSCs in order to estab-
lish the treatment strategy for use in rheumatic diseases.
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